Glenmark Of India, Forest Of U.S. Say COPD Drug Fails Phase II Trials
This article was originally published in PharmAsia News
Executive SummaryIndia's Glenmark Pharmaceuticals and U.S.-based Forest Laboratories said their drug to treat chronic obstructive pulmonary disease has failed to achieve goals in a Phase II clinical trial. The two drug makers were looking to the oglemilast drug for treating COPD as a potential blockbuster. It would have competed with Pfizer's Spiriva (tiotropium bromide), which, without competition, is expected to generate nearly $5 billion in annual sales by 2015. (Click here for more
You may also be interested in...
Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.
The court included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider decisions in civil litigation and convictions in criminal cases. However, Amarin still eyes curbing competition from omega-3 supplements.
Senate's Over-the-Counter Monograph Safety, Innovation, and Reform Act goes next for consideration by House, which has had a bill by the same title on its floor for a vote since it was passed by Energy and Commerce Committee in late June.